Late hiatal hernia after Roux-en-Y gastric bypass: a systematic review.

Surg Obes Relat DisJun 4, 2026 (epub)
Clinical ResearchGastroenterologyGeneral Surgery

Pedro Bicudo Bregion, Josélio Rodrigues de Oliveira-Filho, João Gabriel Romero Braga et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review examined late hiatal hernia (HH) after Roux-en-Y gastric bypass (RYGB) in patients with obesity. The study found that HH is associated with gastroesophageal reflux disease (GERD) in 39-93.6% of cases and obstructive symptoms in 29%-88%. Postoperative symptom resolution rates varied from 42.9% to 100%, with recurrence rates between 5% and 6.54%.

Key findings

  • HH presents with GERD in 39-93.6% of cases and obstructive symptoms in 29%-88%.
  • Postoperative symptom resolution rates range from 42.9% to 100%.
  • HH recurrence occurs in 5%-6.54% of cases.
  • Bioabsorbable mesh may reduce recurrence rates.

Why it matters

Understanding the prevalence and management of late hiatal hernia after RYGB is crucial for clinicians, as it can significantly impact patient outcomes and quality of life. Effective diagnosis and treatment strategies are essential for addressing associated symptoms.

Source

PubMed · PMID 42379986

Published in Surg Obes Relat Dis. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Gastroenterology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.